Please login to the form below

Not currently logged in
Email:
Password:

Abbott to acquire Facet Biotech

Abbott is to acquire Facet Biotech in a deal valued at approximately $722m, strengthening Abbott's capabilities in biologics in immunology and oncology

Abbott is to acquire Californian-based Facet Biotech in a deal valued at approximately $722m. The move will strengthen Abbott's capabilities in biologics in immunology and oncology.

The acquisition gives Abbott access to daclizumab, a mid-stage biologic being developed in collaboration with Biogen Idec for the treatment of patients with multiple sclerosis. The drug is expected to move into phase III testing in the second quarter of 2010.

Facet's oncology portfolio includes several compounds being developed in collaboration with other partners, and will complement Abbott's own compounds in mid- to late-stage trials, including ABT-263, ABT-888, and ABT-869.

Under the terms of the agreement, Abbott will begin a tender offer to purchase all outstanding shares in Facet Biotech at $27 per share in cash, resulting in a net cost of about $450m. The stock offer represents a 67 per cent premium to Facet's closing share value on Tuesday. In addition, the purchase price includes $272m, representing Facet Biotech's projected cash and securities.

The deal is expected to close in the second quarter of 2010.

10th March 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics